News

The article entitled “Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial” has been published in PLoS One and is available on the journal’s website (https://doi.org/10.1371/journal.pone.0179538. The article reports the results of a Phase 2 study of tesamorelin in HIV-uninfected patients with Type 2 diabetes.